Myocardial Infarction Clinical Trial
— PRO-GR-4Official title:
Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)and Presenting With High Platelet Reactivity, as Assessed With a Point of Care Assay, After 600mg Clopidogrel Loading Dose
Verified date | September 2011 |
Source | University of Patras |
Contact | n/a |
Is FDA regulated | No |
Health authority | Greece: Ethics Committee |
Study type | Interventional |
This is a single-center, randomized, single-blind, investigator-initiated, pharmacological
study with a parallel design. Patients with ST elevation myocardial infarction undergoing
primary percutaneous coronary intervention and presenting high platelet reactivity as
assessed with the Verify Now P2Y12 assay-Accumetrics(Platelet Reactivity Units -PRU≥235) at
2 hours post-clopidogrel 600mg LD (Day 0), as assessed with the Verify Now P2Y12 assay, will
be randomized after informed consent, in a 1:1 ratio to the following treatment groups:
Group Α: Clopidogrel 150mg per day,starting from Day 1 until Day 5 (5 days after
randomization) Group Β: Prasugrel 60 mg immediate loading (on Day 0) followed by 10mg/day
starting from Day 1 until Day 5 (5 days after randomization).
Platelet reactivity assessment will be performed 2 hours after randomization (Day 0), 24 h
after randomization (Day 1) and on Day 5. Documentation of major adverse cardiac events
(death, myocardial infarction, stroke, revascularization procedure with PCI or CABG)and
serious adverse events (bleeding, other adverse events)will be performed until Day 5.
Status | Completed |
Enrollment | 35 |
Est. completion date | September 2011 |
Est. primary completion date | September 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: 1. Age =18 years old 2. Patients with STEMI undergoing primary PCI with stenting 3. Platelet reactivity in PRU =235 2 hours post 600 mg clopidogrel loading dose 4. Informed consent obtained in writing Exclusion Criteria: 1. Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the Day 5. 2. Pregnancy 3. Breastfeeding 4. Inability to give informed consent or high likelihood of being unavailable until Day 5. 5. Cardiogenic shock 6. Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (pseudoaneurysm, arteriovenous shunt, retroperitoneal bleeding or hematoma >5 cm at the arterial catheter insertion site), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by = 5 gr/ dl or intracranial bleeding). 7. Unsuccessful PCI (residual stenosis > 30% or flow < ???? 3) or planned staged PCI in the next 5 days after randomization 8. Requirement for oral anticoagulant prior to the Day 5 9. Current or planned therapy with other thienopyridine class of ADP receptor inhibitors. 10. Known hypersensitivity to prasugrel or ticagrelor 11. History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months. 12. Other bleeding diathesis, or considered by investigator to be at high risk for bleeding on thienopyridine therapy. 13. Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm). 14. Thrombocytopenia (<100.000 / µL) at randomization 15. Anaemia (Hct <30%) at randomization 16. Polycythaemia (Hct > 52%) at randomization 17. Periprocedural IIb/IIIa inhibitors administration 18. Severe allergy to contrast agent, unfractionated heparin, enoxaparin or bivalirudin that cannot be adequately premedicated. 19. Recent (< 6 weeks) major surgery or trauma, including GABG. 20. Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study. 21. INR>1.5 at randomization |
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Greece | Patras University Hospital | Patras |
Lead Sponsor | Collaborator |
---|---|
University of Patras |
Greece,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Platelet reactivity | Platelet Reactivity assessed by VerifyNow P2Y12 assay 24 hours post randomization | 24 hours post randomization (Day 1) | No |
Secondary | Platelet reactivity | Platelet Reactivity assessed by VerifyNow P2Y12 assay 2 hours post randomization | 2 hours post randomization (Day 0) | No |
Secondary | Platelet reactivity | Platelet reactivity assessed by VerifyNow P2Y12 assay 5 days post randomization | 5 days post randomization (Day 5) | No |
Secondary | Hyporesponsiveness rate | Hyporesponsiveness rate (PRU=235 assessed with the VerifyNow P2Y12 assay)2 hours post randomization | 2 hours post randomization (Day 0) | No |
Secondary | Hyporesponsiveness rate | Hyporesponsiveness rate (PRU=235 assessed with the VerifyNow P2Y12 assay)24 hours post randomization | 24 hours post randomization (Day 1) | No |
Secondary | Hyporesponsiveness rate | Hyporesponsiveness rate (PRU=235 assessed with the VerifyNow P2Y12 assay)5 Days post randomization | 5 days post randomization (Day 5) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Completed |
NCT04507529 -
Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients
|
N/A | |
Recruiting |
NCT06066970 -
Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
|
||
Recruiting |
NCT03620266 -
Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI
|
N/A | |
Completed |
NCT04097912 -
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
|
||
Completed |
NCT04153006 -
Comparison of Fingerstick Versus Venous Sample for Troponin I.
|
||
Completed |
NCT03668587 -
Feasibility and Security of a Rapid Rule-out and rule-in Troponin Protocol in the Management of NSTEMI in an Emergency Departement
|
||
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Recruiting |
NCT05371470 -
Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation
|
N/A | |
Recruiting |
NCT04562272 -
Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP
|
N/A | |
Completed |
NCT04584645 -
A Digital Flu Intervention for People With Cardiovascular Conditions
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT06007950 -
Time-restricted Eating Study (TRES): Impacts on Anthropometric, Cardiometabolic and Cardiovascular Health
|
N/A | |
Withdrawn |
NCT05327855 -
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
|
Phase 2 | |
Recruiting |
NCT02876952 -
High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients
|
N/A | |
Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
Completed |
NCT02711631 -
Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02382731 -
Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction
|
N/A | |
Completed |
NCT02552407 -
Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis
|
N/A |